Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Lung Neoplasms"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle&page=11
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle&page=11
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle&page=11
PubPharm (6.438)
101
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) : Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours (TROPION-PanTumor02)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
102
Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify TDLN in Early-stage NSCLC : Injection of 99mTc-nanocolloid and ICG to Identify, Retrieve and Qualify Tumor Draining Lymph Nodes in Early-stage Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
103
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) : A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
104
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance : Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance in Non-Squamous Locally Advanced Non-Small Cell Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
105
The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer : A Preliminary Study on the Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
106
Study of Low-Dose Radiotherapy Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With ES-SCLC : Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Serplulimab for Patients With Extensive-Stage Small Cell Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
107
A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 : A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
108
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) : Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
109
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer : A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
110
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC : Neoadjuvant Almonertinib Followed by Adebrelimab-based Chemo-immunotherapy in II-IIIB EGFR-mutant Non-small Cell Lung Cancer, a Single Arm, Phase II Study
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
[1]
« Vorheriger
6
7
8
9
10
11
12
13
14
15
16
Nächster »
[644]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Lung Neoplasms
Medienart
6.438
Aufsätze
6.438
E-Artikel
6.438
E-Ressourcen
Zeitschriftentitel
6.438
ClinicalTrials.gov
Thema
6.438
610
Lung Neoplasms
5.162
Study Type: Interventional
3.618
Carcinoma, Non-Small-Cell Lung
2.315
Recruitment Status: Completed
1.970
Phase: Phase 2
1.574
Recruitment Status: Recruiting
1.212
Study Type: Observational
778
Phase: Phase 1
737
Small Cell Lung Carcinoma
696
Recruitment Status: Terminated
655
Phase: Phase 3
653
Medical Condition: Lung Cancer
640
Recruitment Status: Active, not recruiting
529
Recruitment Status: Unknown status
429
Carcinoma
396
Recruitment Status: Not yet recruiting
349
Medical Condition: Non-small Cell Lung Cancer
291
Phase: Phase 1, Phase 2
281
Medical Condition: Non Small Cell Lung Cancer
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
3.936
2020-
2.387
2010-2019
115
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
6.438
Englisch
Haven't found what you're looking for?
Wird geladen...